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ABSTRAK
Infark miokard merupakan salah satu penyebab kematian utama di banyak negara. Oleh karena itu, terapi 
yang efektif untuk infark miokard sangatlah diperlukan. Saat ini, terapi reperfusi dan pengobatan konvensional 
merupakan pendekatan utama pada infark miokard. Namun, banyak pasien yang tidak memberikan respons yang 
baik terhadap terapi ini. Kardiomioplasti seluler merupakan terapi baru dengan menggunakan sel punca untuk 
perbaikan jantung. Sel punca merupakan terapi yang potensial untuk menyelamatkan sel jantung yang rusak. 
Berdasarkan penelitian yang ada, sel punca merupakan pilihan yang potensial untuk infark miokard. 
Namun, terdapat beberapa tantangan yang perlu dijawab sebelum terapi ini dapat diaplikasikan secara luas. 
Seiring dengan bertambahnya pengetahuan kita tentang sel punca, maka berbagai pertanyaan yang ada akan 
terjawab, dan pada akhirnya memberikan solusi terbaik untuk pengobatan penyakit jantung iskemik. Ulasan 
artikel ini memaparkan berbagai perkembangan terbaru tentang terapi sel punca untuk pasien infark miokard.
Kata kunci: sel punca, kardiomioplasti selular, infark miokard.
ABSTRACT
Myocardial infarction is one of the main cause of mortality in many countries. Therefore, an effective therapy 
for myocardial infarction is required. Reperfusion and other conventional therapy have been the mainstay therapy 
for myocardial infarction. However, many patients remain refractory to this therapy. Cellular cardiomyoplasty is 
considered a novel therapy, in which stem cells are used for cardiac repair. Stem cells are potential therapeutic 
approach that could be the ultimate solution for salvaging damaged cardiomyocyte. 
Based on current studies, stem cells are a promising therapeutic approach for myocardial infarction. However, 
some challenges need to be answered by future studies before this novel therapy can be widely applied. As we 
advance our understanding, all questions behind stem cell therapy would finally be revealed, and eventually 
provide the ultimate solution for ischaemic cardiac repair. This paper provide an overview of the latest progress 
in stem cell therapy for myocardial infarction.
Key words: stem cells, cellular cardiomyoplasty, myocardial infarction.
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INTRODUCTION
Stem cells technology used to be an 
untouched realm of medicine. Until recently, 
the robust potential of stem cells were still a 
mystery, but today, we are constantly getting new 
information on this particular topic. The prospect 
of stem cell therapy is so vast, one of which is to 
treat damaged cardiomyocyte.1,2
Acute myocardial infarction is one of the 
main causes of mortality and morbidity in 
many countries. Not only this disease causes a 
massive socio-economic burden, but also reduces 
the quality of live for patients who survive the 
attack.3 Currently, one of the mainstay therapy for 
myocardial infarction is rapid revascularization 
to limit ischaemic damage.
Reperfusion and other conventional therapy 
have undoubtedly saved so many lives, yet there 
are patients remained refractory to this therapy and 
left with no other treatment options. In addition 
to that, many patients who have underwent 
reperfusion strategy and survived, often left with 
significant impairment of left ventricular systolic 
function. One big question remain unanswered. Is 
there any other treatment option for these patients? 
Medical therapeutic approach to reduce damaged 
cardiomyocyte and generate new functioning 
muscle is the current unmeet need.
Stem cells emerge as the novel procedure 
to restore damaged cardiomyocytes, and this 
procedure is popularly known as cellular 
cardiomyoplasty.4,5 Many clinical trials have 
documented the potential use of stem cells to 
generate viable cardiomyocyte and improve 
cardiac function.6-7 To date, there are many 
different types of adult stem cells and progenitor 
cells used for this procedure, some of which are 
bone marrow derived stem cells, hematopoietic 
stem cells, mesenchymal stem cells and so on. 
Since the advance of stem cells technology is 
faster than ever before, this review aimed to give 
an evidence based update on stem cells use for 
myocardial infarction, what have we achieved 
so far, and what does the future hold for this 
breakthrough.
CELLULAR CARDIOMYOPLASTY
Cellular cardiomyoplasty is a cell therapy 
using stem cells or progenitor cells for myocardial 
regeneration. After an ischaemic attack due to 
occluded coronary vessels, heart muscle usually 
left damaged and nonfunctioning. However, 
recent evidence suggested that the cardiac muscle 
could actually undergo a limited amount of 
renewal. A prospect of inducing muscle cell to 
undergo division for cardiomyocyte replacement, 
or generating new muscle by stem cells are 
certainly intriguing.8,9
Stem cells are capable to proliferate in 
the same state (self-renewal) and differentiate 
into multiple cell lineages. On the other hand, 
progenitor cells are more specific and have 
limited differentiation potential. Mechanism 
on how stem cells work are as follows: firstly, 
these stem cells need to be extracted from the 
source (eg. bone marrow), after that these stem 
cells need to be delivered to the injured area. 
These cells are implanted in the myocardium, 
and due to the nature of these cells, they would 
grow and differentiate/transdifferentiate into 
cardiomyocyte. To achieve the goal of cardiac 
repair, these cells should also have the ability 
to fuse with the surrounding tissues that 
their harmonious contraction increases the 
heart contraction. Furthermore, these newly-
formed cardiomyocyte should also express 
the appropriate electromechanical properties 
required for contraction to yield a synchronous 
contraction.5,10
Many clinical studies have documented the 
feasibility and safety of cellular cardiomyoplasty 
in patients with coronary artery disease.10-12 There 
is wide arrays of cell types being used for cellular 
cardiomyoplasty and the exact efficacy of each 
cell type is yet to be determined. To date, there 
are some different types of adult stem cells and 
progenitor cells used for this procedure, some 
of which are bone marrow derived stem cells, 
hematopoietic stem cells, mesenchymal stem 
cells and many others.12-14
POTENTIAL SOURCE AND TYPE OF STEM 
CELLS
Bone Marrow Derived Stem Cells
Bone marrow derived stem cells (BMCs) are 
the most widely studied type of stem cells. Orlic 
et al. first describe the ability of bone marrow 
cells to regenerate infarcted myocardium in 
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mouse models. The transplanted cells showed 
transdifferentiation into cardiomyocyte which 
eventually lead to improved left ventricular 
ejection fraction.15 The three types of stem cells 
derived from bone marrow are hematopoietic 
stem cells (HSCs), mesenchymal stem cells 
(MSCs), and endothelial progenitor cells 
(EPCs).15-17
The role of BMCs for acute myocardial 
infacrtion has been reported to improve left 
ventricular ejection fraction (LVEF), both in 
REPAIR-AMI and BOOST trial.18,19 BOOST 
trial demonstrate an acceleration of LVEF 
after intracoronary BMCs transfer (ejection 
fraction increased by 6.7% in the BMCs group 
as compared to 0.7% in the control group), and 
significant result was sustained until 18 months.18 
While in REPAIR AMI trial, improvement 
of LVEF, infarct size and wall thickening of 
infarcted segments were reported at two years 
follow up. At two years, the cumulative end point 
of death, myocardial infarction, or necessity for 
revascularization was significantly reduced in 
the BMC group compared with placebo (hazard 
ratio, 0.58; 95% CI, 0.36 to 0.94; P=0.025).20,21 
The long term effect of intracoronary 
stem cell application was also under studied. 
Strauer BE et al.22 in a study named the 
STAR-heart, a non-randomized study reported 
that intracoronary BMCs therapy improves 
ventricular performance, quality of life and 
survival in patients with heart failure. BMCs 
therapy was not associated with any adverse 
effect during the 5-year. Feng Cao et al.23 reported 
long-term myocardial functional improvement 
after autologous bone marrow mononuclear 
cells transplantation in eighty-six patients with 
STEMI that were randomized to receive BMCs 
or saline. After four years, the improved LVEF 
was still sustained.23 Long term benefit of BMC 
transplantation was further confirmed by the 
BALANCE study. In this study, intracoronary 
autologous bone marrow cell transplantation in 
patients with acute myocardial infarction was 
associated with a higher ejection fraction, and a 
lower mortality at 5-year.24
Skeletal Myoblast
Skeletal muscle has the ability to regenerate 
under certain circumstances. Skeletal resident 
stem cells are usually known as satellite cells, and 
these cells would differentiate to new myocytes 
in response to injury. However, whether this 
ability can be translated to a different condition, 
as in cardiomyocyte repair, should be further 
studied.25,26
MAGIC trial, a randomized controlled phase 
II trial, showed no significant changes in terms 
of global and regional LV function in skeletal 
myoblast-treated patients.27 Another study 
performed by Dib et al.28 showed an increased 
in LV ejection fraction in the group treated with 
transepicardial injection of autologous SMs.28
One downside of using skeletal myoblasts 
(SMs) is its pro-arrhytmogenic effect. This 
effect was observed by Meanasche et al.29 One 
possible mechanism by which SMs may caused 
cardiac electrical discordance is the failure 
of SMs to couple electrically with adjacent 
cardiomyocyte after being transplanted to the 
heart. This group of transplanted cells with 
different electrophysiology properties might 
contributed to the pro-arrhytmogenic effect of 
SMs.30,31 However, according to MAGIC trial 
there was no significant increased in arrhytmic 
events in the intervention group, however an 
increased trend towards arrhytmic events was 
recorded.27
Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are another 
potential option for cellular cardiomyoplasty. 
Mesenchymal stem cells can be found in various 
tissue, such as bone marrow and adipose tissue.32 
One interesting mechanism by which MSCs 
mediate cardiac function improvement is the 
paracrine effect. MSCs may secrete soluble 
cytokines and growth factors that would 
eventually influence adjacent cardiomyocyte.33
Hare JM et al.34 studied the efficacy of 
intravenous allogenic human mesenchymal 
stem cells in patients with myocardial infarction. 
According to this study, intravenous MSCs were 
safe as showed by the similar adverse event rates 
in both intervention and control group. MSCs 
treated patients also present with a better ejection 
fraction and improved pulmonary function, as 
showed by increased forced expiratory volume 
in 1 second.34 In another study, named The 
POSEIDON trial, Hare JM et al.34 showed that 
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transendocardial injection of allogeneic and 
autologous MSCs without a placebo control 
were both associated with low rates of treatment-
emergent serious adverse effects, including 
immunologic reactions. The alloimmune 
reactions in patients receiving allogeneic MSCs 
for ischemic LV dysfunction were low (3.7%). 
In summary, MSCs injection favorably affected 
patient functional capacity, quality of life and 
LV remodeling.35
Another interesting source of stem cells is 
the adipose tissue, namely adipose tissue derived 
stem cells (ADSCs). The characteristics of 
ADSCs are generally similar to MSCs, though 
not identical.36 One study to investigate the safety 
of ADSCs is the APOLLO trial. In this trial, 
patients who had undergone the first episode of 
myocardial infarction, with an ejection fraction 
of <50%, will be underwent liposuction within 
24 hours of percutaneus intervention. ADSCs 
that were extratcted during liposuction would 
eventually injected intracoronary to the patient’s 
heart. According to this study, the infarct size was 
significantly reduced in the treatment arm and 
was still sustained after 18 months follow up. 
Perfusion of the infarcted heart, as measured by 
single photon-emission computed tomography 
(SPECT), showed significant improvement as 
well. This study concluded that ADSCs can 
be safely obtained and administered to the 
patients.37 Another studies named ADVANCE, 
still on-going during the preparation of this 
manuscript, and will provide further information 
regarding the efficacy of this approach on a 
larger population, since this study enroll up to 
370 patients.
The administration MSC present one 
particular advantage over the other type of stem 
cells, that in the case of MSC use, it is possible 
to use allogenic graft. This fact is due to the lack 
of various major histocompability complex and 
costimulatory cell-surface antigens in MSCs.38 
However negative experience with MSCs use 
was documented by Fischer UM et al.39 whom 
aimed to track the journey of stem cells after 
intravenous infusion. MSCs were labeled using 
a cell labeling kit. Infrared imaging system 
was used to identify the presence of labeled 
cells. According to this study, the majority of 
MSCs were trapped inside the lungs following 
intravenous infusion.39
The negative finding documented by Fischer 
UM et al. suggested a more cautious intepretation 
of positive outcome observed in the study by Hare 
JM et al.35 Some questions remained unanswered, 
if MSCs indeed trapped in the lung, the 
explaination of the positive result of intravenous 
MSCs infusion in the study performed by Hare 
JM et al.35 Need to elaborate more. If intravenous 
administration is not compatible with MSCs, 
the best way to administer MSCs, need to be 
determined.
Endothelial Progenitor Cells
Endothelial progenitor cells (EPCs) have 
been linked with neovascularization in ischemic 
tissue. This interesting finding lead to the use of 
EPCs for another therapeutic purpose like cellular 
cardiomyoplasty.40 The human peripheral blood-
derived EPCs would be a potential approach 
because those cells can be easily isolated without 
the need of major surgical intervention.41
This assumption was later confirmed by 
Badorff et al.17 In this study, Badorff et al. 
reported that EPCs from healthy volunteers 
and Coronary Artery Disease (CAD) patients 
can transdifferentiate into functionally active 
cardiomyocytes when co-cultivated with rat 
cardiomyocytes.17 However, this finding was 
later opposed by Gruh I et al. According to 
this study, there was no significant evidence 
of transdifferentiation of human EPCs into 
cardiomyocyte.42
Whether EPCs possed the ability of 
transdifferentiation into cardiomyocyte still 
required further investigation. A preclinical 
study in rat models by Chang ZT43 showed 
promising result. This study showed that the 
administration of peripheral derived EPCs 
(PB-EPCs) increased cardiac contractility as 
assessed by echocardiography. PB-EPCs are 
able to protect cardiomyocytes through increased 
expression of proteins involved in mediating 
vascular growth.43
Resident Cardiac Stem Cells
Until recently, we believe that heart is a fully 
mature organ with no capability of self-renewal. 
However, the adult heart is not a terminally 
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differentiated organ, but harbors stem cell with 
regenerative capacity, namely resident cardiac 
stem cells (CSCs). Although the origins of 
CSCs are yet unclear, they can be isolated from 
heart tissue and expanded ex vivo for use as a 
cell-based therapy. There were many types of 
CSCs have been described in previous studies, 
like: epicardium-derived cells, cardiosphere-
derived cardiac cells, and cardiac Sca-1+ cells. 
These resident stem cells have the potential to 
differentiate into different types of cells like 
vascular smooth muscle and myocardial cells.44-46
A study in animal model by Oh H et al.47 
documented the beneficial effect of resident stem 
cell therapy in terms of reducing infarct size and 
improving LV function. Given intravenously after 
ischemia/reperfusion, adult heart-derived cardiac 
progenitor cells home to injured myocardium 
and differentiate to myocytes, as shown by the 
positive result of cardiac specific genes (Nkx2.5). 
These cells also expressed α-actin, cardiac 
troponin I and connexin.43,47
Embryonic Stem Cells and Induced 
Pluripotent Stem Cells (iPS)
Embryonic stem cells (ESC) are derived from 
the blastocyst (inner cell mass) of human embryo 
prior to implantation. ESCs are pluripotent 
cells, which means they have the capability 
to differentiate into any cells, one of which is 
cardiac myocytes. Due to the source of these 
cells, there are ethical issues regarding the use 
of ESC.48
The huge potential of ESC comes with a 
price. The pluripotency of ESC made these 
cells predisposes to tumor formation including 
teratomas. Amariglio N et al.49 documented the 
occurence of a human brain tumour following 
neural stem cell therapy. A boy with telangiectasia 
was treated with intracerebellar and intrathecal 
injection of human fetal neural stem cells. Four 
years later, he was diagnosed with a multifocal 
brain tumour. After thorough analysis, the tumor 
was of nonhost origin, indicating it was derived 
from the transplanted neural stem cells.49 To date, 
due to the scarcity of studies on ESC and negative 
experiences of previous studies, the significance 
of ESC as cell-based therapy for myocardial 
infaction remains elusive. The above-mentioned 
limitation would hopefully be elucidated in 
future research.
One possible solution to this ethical issue is by 
reprogamming somatic cells to produce induced 
pluripotent stem cells. Takahashi and Yamanaka 
demonstrated the induction of pluripotent stem 
cells from mouse embryonic or adult fibroblasts 
by introducing four factors (Oct3/4, Sox2, 
c-Myc, and Klf4). They reprogrammed murine 
fibroblast into stem cells with the capacity to 
form all three germ layers, and the term used 
for these cells are induced pluripotent stem cells 
(iPS). The iPS exhibited the morphology and 
growth properties of ESC and expressed ESC 
marker genes.50,51
The therapeutic potential of iPS used to be 
limited into noncardiac diseases, like sickle 
cell anemia, parkinson’s disease and hemofilia 
A. Nelson TJ et al.52 is the first to study the 
use of iPS in acute myocardial infarction in 
mice model. The origin of iPS was mouse 
embryonic fibroblast that was transduced 
with human stemness factor (Oct3/4, Sox2, 
c-Myc, and Klf4). The administration of iPS 
restored postischemic contractile performance, 
ventricular wall thickness, and electric stability. 
The tumour predisposition of these cellswas 
determined in immunocompetent mice, with 
no tumour development observed, whereas in 
immunodeficient mice, tumour development was 
observed, which highlights the importance of 
immune surveillance to prevent tumour growth.52 
Induced pluripotent stem cells exhibit a wide 
arrays of reparative potentials, yet we still need 
to advance our knowledge in cell programming 
and cell fate customasization in order to make 
this approach a safe option for cardiac repair.
Human Umbilical Cord Blood Cells
Human umbilical blood cells (hUCB) 
contains a large number of non-hematopoietic 
stem cells which rarely express human leukcyte 
antigen (HLA) class II antigens, thus reducing 
the risk of rejection. Many studies have reported 
the efficacy and safety of hUCB administration 
in acute myocardial infarction model, with 
conflicting result.53,54
According to Henning RJ et al.53 hUCB 
administration reduce infarction size and 
improve ventricular function in rats without 
requirements for immunosuppression.53 Similar 
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positive finding were documented by Kim et al. 
The study reported improvement in ventricular 
function after intramyocardial hUCB cell 
injection in immunosuppressed infarcted pigs.55 
However, another study done by Moelker et 
al.54 reported contrary result that intracoronary 
administration of hUCB was not associated with 
cardiac improvement in the same animal model.54
Circulating Blood-derived Progenitor cells
Circulating blood-derived progenitor cells 
(CPCs) are similar to BMCs, which mainly 
composed of EPCs. Santoso T et al.9 studied the 
safety and feasibility of combined granulocyte 
colony stimulating factor (G-CSF) and 
erythropoetin (EPO) based-stem cell therapy using 
intracoronary infusion of peripheral blood stem 
cells in patients with recent anterior myocardial 
infarction. G-CSF is used to mobilized stem cells to 
the injured area, inhibits cardiomyocyte apoptosis, 
promotes neovascularization, and increase the 
production of nitric oxide. While EPO, that is 
originally thought to be a hematopoietic hormone 
only, also may inhibited apoptosis and induced 
angiogenesis. This phase I study concluded that 
this procedure is safe and resulted in improved 
endpoints for LV ejection fraction and cardiac 
viability.9
The comparison between BMCs and CPCs 
in terms of efficacy and safety, were performed 
by Assmus B et al.56 (TOPCARE-AMI trial). 
This study reported positive outcome (LV 
global function) in both arms with no significant 
difference.56 A meta-analysis perfomed by Wen 
Y et al.57 to determine the effects of CPCs on 
improvement of cardiac function. According 
to this metanalysis, the administration of 
CPCs provide moderate improvements over 
conventional therapy.57
Cardiopoietic Stem Cells
Cardiopoietic stem cells are not a distinct 
type of stem cells but refer to the novel way of 
processing stem cells in order to get a lineage 
specification. Cardiopoietic stem cells are 
harvested stem cells that are treated with a 
protein cocktail to replicate natural cues to heart 
development, before being injected into the 
patient’s heart. The C-CURE trial studied the 
efficacy of bone marrow derived-mesenchymal 
stem cells in chronic heart failure. The isolated 
mesenchymal stem cells were exposed to a 
cardiogenic cocktail that trigger expression and 
nuclear translocation of cardiac transcription 
factors, before being injected to the patient’s 
heart. After six months follow up, patients in 
the treatment group significantly improved in 
terms of LVEF and fitness capacity. There was 
no evidence of increased cardiac or systemic 
toxicity induced by cardiopoietic cell therapy.58 
Unfortunately, data comparing the efficacy 
and safety between cardiopoietic stem cells 
and ordinary stem cells without cocktail-based 
priming is still lacking.
DELIVERY METHODS 
In order to make these stem cells reach the 
heart, a reliable delivery method need to be 
employed. The ideal method should be able to 
safely and efficiently deliver an optimal number 
of stem cells to the target tissue. Beside the 
high efficacy, this delivery method should be 
as minimally invasive as possible for the sake 
of patients’ comfort. There are some delivery 
methods worthy to know.
Intracoronary Infusion
As the name implies, intracoronary infusion 
is a process of delivering stem cells through 
coronary artery, usually through intracoronary 
catheterization. Stem cells are infused under 
pressure via a ballon catheter. The ballon was 
inflated in order to prevent anterogade blood 
flow that would compromize stem cells delivery. 
Catheter guided cell transfer has its unique 
advantage of safety under local anesthesia, 
and a part of routine cardiac catheterization. 
The intracoronary method provide a maximum 
number of cells to the target area, with good 
blood supply which is crucial for cell survival. 
Multiple studies have reported the use of 
intracoronary infusion for stem cells delivery.11,19
Strauer BE et al. and Schächinger V et al. 
reported improved outcome in acute myocardial 
patients after BMCs intracoronary infusion. 
Improved parameters in these studies include 
LV function and infarct size.11,19 Grieve SM 
et al. reported microvascular obstruction after 
MSCs delivery through intracoronary route. 
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As previously discussed, MSCs are large 
cells that might induce myocardial damage by 
microvascular obstruction. This finding raise 
another question of which delivery method is 
the best for each type of stem cells.60
Intravenous Peripheral Infusion
Intravenous stem cells administration is 
one of the easiest method to be employed. 
Intravenous administration is possible through 
homing phenomenon of stem cells to the injured 
Figure 1.  Clinical trials on stem cells over the years. The focus of research shifted from finding non-cardiac progenitors towards 
finding cardiac cells and putative cardiac progenitors.59
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heart. Homing is a process where cells migrate 
to the organ of their origin. Homing of bone 
marrow stem cells to injured myocardium is 
now also thought to occur after myocardial 
infarction.51,61 This process is believed to be 
a multistep complex process involving many 
cytokines and granulocyte colony-stimulating 
factor (G-CSF), that usually rise more intense in 
acute settings. Orlic et al15 studied the potential of 
BMC mobilized by stem cell factor and G-CSF 
in mice with infracted heart. The resulted in the 
intervention group, was significant decrease of 
mortality, reduced infarct size and improved 
ejection fraction.15
Unfortunately, intravenous peripheral 
infusion comes with some disadvantages. First, 
only 3% of normal cardiac output will flow 
per minute through the left ventricle. This low 
amount of blood would limit the amount of stem 
cells delivered. Secondly, due to the passing of 
venous blood in the lung, many cells would trap 
in lung vasculature that eventually lead to stem 
cells reduction.60 One obvious example is the 
trapping of big-sized MSCs in lung, as clearly 
demonstrated by Fischer UM et al.39
Intramyocardial, Transendoccardial and 
Transpericardial Route
As mentioned earlier, the downside of 
intravenous administration is the passing of 
the blood in certain organs that would entraped 
some of the stem cells. Unlike intravenous route, 
intramyocardial method is undoubtly provide 
direct access to the injured cardiomyocyte 
bypassing the need for mobilization, homing 
and any risk of cells entrapment in other organ, 
thus provide a more effective way to deliver 
abundant stem cells to the injured area. However, 
this method comes with its own expense of a 
more invasive method, not to mention the risk 
of ventricular perforation in the already damaged 
cardiomyocyte. Intramyocardial delivery usually 
performed during an open heart surgery or 
needle-tipped delivery catheter.61,62 Nelson et 
al.52 documented that intamyocardial delivery of 
iPS originating from reprogrammed fiobroblast, 
yielded progeny that properly engrafted and 
resulted in restored contractile performance, 
increased ventricular wall thickness, and electric 
stability.52
Transendocardial and transpericardial route 
have been explained in some animal studies.63 
One particular advantage of this method is the 
visualization and the chance of administering 
stem cells directly to the target area. Perin EC 
et al.21 elaborate the transendocardial BMCs 
administration in patients with ischemic heart 
disease. The injection catheter advanced into 
the left ventricle through the aortic valve, then 
the catheter tip is placed against the endocardial 
surface and this procedure is finalized with 
needle extention into the myocardium to 
deliver the BMCs. This study concluded that 
transendocardial route was a safe way to transfer 
BMCs and resulted in improved ejection fraction 
and global left ventricular function.21
STUDIES USING STEM CELLS IN MYOCARDIAL 
INFARCTION
Many studies have been carried out to 
investigate the efficacy and safety of stem cell 
therapy in patients with myocardial infarction. 
Each of these studies investigated different 
kind of stem cells with different delivery 
methods. The ultimate goal of these studies 
is to answer whether stem cell therapy could 
be a feasible therapeutic approach for patients 
with myocardial infarction. The result of these 
studies were not always positive, even some of 
the studies did not document any beneficial effect 
of stem cell therapy. However, this conflicting 
result need to be intepreted with caution due 
to the different study method, different type of 
stem cells used, and different delivery methods 
employed. Table 1 summarize some studies on 
stem cells therapy for myocardial infarction, that 
have been performed.
Three meta-analysis on the efficacy of 
BMCs therapy for myocardial infarction 
have been published. In a meta-analysis by 
Delewi R et al, intracoronary BMCs infusion 
is associated with improvement of LV function 
and remodelling in patients after ST-segment 
elevation myocardial infarction. The benefit 
in terms of LVEF improvement was more 
pronounced in patients with a worse baseline 
LVEF (LVEF cut off: 40%) and younger age 
(age cut off: 55 years).68 In a second meta-
analysis by Clifford DM et al.69 which include 
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Figure 2. Delivery methods for cellular cardiomyoplasty with their advantages and disadvantages.59
thirty-three RCTs, there was no significant 
difference in hard end point like mortality and 
morbidity in the BMCs treated group. However 
global heart function, as represented by LVEF 
and infarct size, was improved significantly and 
was sustained long term (12 to 61 months) in the 
BMCs group.69 The third meta-analysis by Long 
C et al.70 further confirmed the beneficial effect 
of intracoronary BMCs in patients with acute 
myocardial infraction. According to this meta-
analysis, BMCs therapy significantly improved 
LVEF, while mildly but not significantly reduced 
left ventricular end-systolic volume and left 
ventricular end-diastolic volume.70 These three 
meta-analysis synonymously agree that BMCs 
therapy is beneficial in terms of improved heart 
function and reduced infarct size.
CHALLENGES AND THE FUTURE
We have just entered the new era of stem 
cell therapy. When advanced therapy like 
primary PCI and thrombolytic showed more 
limited beneficial for patients with myocardial 
infarction, the concept of cell-based therapy is 
definitely appealing. This new approach could be 
the answer that have been waited for sometime. 
As we have discussed previously, there are 
many issues on stem cell therapy that need to 
be addressed in future studies. Firstly, what is 
considered to be the best stem cells to replace 
cardiomyocyte. Secondly, the right delivery 
method of these stem cells need to be determined. 
Whether different type of stem cells required 
certain delivery methods also need to be further 
elucidated. Another question is the right timing 
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Intracoronary 18 months • Significant increase of LVEF in the BMC 
group after 6 months.
• This effect is not sustained after 18 months
REPAIR-
AMI (2006)19
AMI patients  
(187 patients)
Intracoronary 1 year • Significant increase of LVEF in the BMC 
group after 4 months.
• At 1 year, BMC group was associated with 
a reduction in the prespecified combined 







Transendocardial 6 months • Significant increase in LVEF in the 
treatment group (2.7 ± 5.2%; P = 0.030; 
95% CI, 0.27 to 5.07).





CHF patients  
(391 patients)
Intracoronary 5 years • Intracoronary BMC therapy improves 
ventricular performance, quality of life and 
survival in patients with heart failure. No 
side effects were observed
Ramshorst 




Intramyocardial 3 months • Significant increase in LVEF in the BMC 
group (52±5% versus 51±7%, P=0.001).
TIME trial 
(2012)65
AMI patients  
(120 patients)
Intracoronary 6 months • No significant difference in LVEF or global 
LV function between both arms




Intravenous 6 months • The MSCs treated group demonstrated 
significant improved LVEF, and global 
symptom score, as compared to that in the 
placebo group.






Intracoronary 1 year • The initial result showed significant 
improvement in terms of LVEF and qualitu 
of life in the treatment group.





Intracoronary 6 months • No increase in EF over control at 6 months 
follow up.





Intracoronary 6 months • The SM treated group demonstrated 
increased cardiac function as showed by 
increase LVEF.








Transendocardial 6 months • This study is premturely halted due to 
financial issue. However, a completed-
analysis reported favorable outcome in the 
SMs treated group, in terms of the distance 
during 6 minute walk. No difference in 
LVEF, wall motion and LV dimension 





Intracoronary 4 months • The CPCs treated group showed significant 
increased global LVEF, improved regional 
wall motion and reduced end systolic LV 
volume.
Abbreaviation: BMCs: bone marrow derived stem cells; MSCs: mesenchymal stem cells; CSCs: resident cardiac stem cells; SMs: 
skeletal myoblast; CPCs: circulating blood-derived progenitor cells; LVEF: left ventricular ejection fraction; LVESV: left ventricular 
end-systolic volume; MVO2;G-CSF: granulocyte colony stimulating factor
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of delivery (acute, sub acute or chronic), whether 
it contributes to the fate of stem cells. Fourth, 
the concentration of stem cells, dose-effect 
relationship and safety of stem cell therapy need 
to be further investigated. One particular topic in 
regard to stem cell safety is the tumorigenicity 
of ESC. We need to disentangle a way to 
reprogram these cells so they can differentiate 
into functional cells, but lack the ability to form 
tumours. Finally, novel diagnostic tools are 
required to detect and evaluate stem cells therapy. 
Future studies would hopefully provide solid 
proof on hard end-points (eg. mortality), instead 
of surrogate markers like LVEF or infarct size. 
CONCLUSION
Tremendous progresses were made in 
cell-based therapy, and future advances would 
further lead us to a new solution for ischaemic 
heart disease. Stem cells own robust potential in 
medicine, one of which is to replace damaged 
cardiomyocyte. More evidents are needed in 
advance to widely use of this modality.
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